Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Life SciencesNSE:SAILIFE -0.09%18 Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 78.95% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sai Life Sciences's Debt-to-EBITDA or its related term are showing as below:
NSE:SAILIFE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.42 Med: 2.95 Max: 6.46
Current: 0.42
During the past 5 years, the highest Debt-to-EBITDA Ratio of Sai Life Sciences was 6.46. The lowest was 0.42. And the median was 2.95.
NSE:SAILIFE's Debt-to-EBITDA is ranked better than 78.95% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs NSE:SAILIFE: 0.42
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sai Life Sciences Debt-to-EBITDA Related Terms
Sai Life Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Sai Life Sciences (NSE:SAILIFE) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sai Life Sciences. Over the past decade, Sai Life Sciences' Debt-to-EBITDA has ranged from 0.42 to 6.46. According to the industry distribution chart, Sai Life Sciences ranks #24 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 21.1%.
Is Sai Life Sciences' Debt-to-EBITDA too high?
Sai Life Sciences' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 6.46. Based on the distribution chart, Sai Life Sciences ranks #24 out of 114 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #24 out of 114 companies for Debt-to-EBITDA. This places Sai Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.32. Historically, Sai Life Sciences' own Debt-to-EBITDA has ranged from 0.42 to 6.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sai Life Sciences. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Sai Life Sciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
